Literatur
-
1
Forman L M, Simmons D A, Diamond R H.
Hepatic
failure in a patient taking rosiglitazone.
Ann Intern
Med.
2000;
132
118-121
-
2
Al-Salman J, Arjomand H, Kemp D G, Mittal M.
Hepatocellular injury
in a patient receiving rosiglitazone. A Case report.
Ann
Intern Med.
2000;
132
121-124
-
3
Füchtenbusch, M, Standl E, Schatz H.
Clinical
efficacy of new thiazolidinediones and glinides in the treatment
of type 2 diabetes mellitus.
Exp Clin Endocrinol Diabetes.
2000;
108
151-163
-
4
Phillips L S, Grunberger G, Miller E, Patwardhan R, Rappaport E B, Salzman A. Rosiglitazone Clinical Trials
Study Group .
Once- and twice-daily dosing with rosiglitazone
improves glycemic control in patients with type 2 diabetes.
Diabetes
Care.
2001;
24
308-315
-
5
Wolffenbuttel B H, Gomis R, Squatrito S, Jones N P, Patwardhan R N.
Addition
of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic
control in Type 2 diabetic patients.
Diabet Med.
2000;
17
40-47
-
6
Lehmann J M, Moore L B, Smith-Oliver T A, Wilkison W O, Willson T M, Kilewer S A.
An antidiabetic
thiazolldinedione is a high affinity ligand for peroxisome proliferator-activated
receptor gamma (PPAR gamma).
J Biol Chem.
1995;
270
12953-12956
-
7
Parulkar A A, Pendergrass M L, Granda-Ayala R, Lee T R, Fonseca V A.
Nonhypoglycemic
effects of thiazolidinediones.
Ann Intern Med.
2001;
134
61-71
-
8
Tontonoz P, Nagy L.
Regulation of macrophage
gene expression by peroxisome-proliferator-activated receptor gamma:
Implications for cardiovascular disease.
Curr Opin Lipidol.
1999;
10
485-490
Korrespondenz
Priv.-Doz. Dr. Martin Pfohl
BG-Kliniken Bergmannsheil Medizinische Universitätsklinik Kernklinik,
Endokrinologie und Stoffwechsel
Bürkle-de-la-Camp-Platz 1
44789 Bochum
